ArticleClinical cancer research : an official journal of the American Association for Cancer Research2012
Two sides of the same coin: EGFR exon 19 deletions and insertions in lung cancer.
Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 17 citations in OpenAlex.
- Targeting exon mutations in NSCLC: clinical insights into LAG-3, TIM-3 pathways, and advances in fourth-generation EGFR-TKIs.Medical oncology (Northwood, London, England) · 2025Review
- A new approach for the detection of genetic alterations utilizing modified loop-mediated isothermal amplification reaction (LAMP).Scientific reports · 2025Article
- Ethyl acetate extract ofFrontiers in pharmacology · 2025Article
- Non-small cell lung cancer cells with uncommon EGFR exon 19delins variants respond poorly to third-generation EGFR inhibitors.Translational oncology · 2024Article
- Targeting the Epidermal Growth Factor Receptor in EGFR-Mutated Lung Cancer: Current and Emerging Therapies.Cancers · 2021Review
- Molecular Characteristics and Clinical Outcomes of EGFR Exon 19 C-Helix Deletion in Non-Small Cell Lung Cancer and Response to EGFR TKIs.Translational oncology · 2020Article
- Differential significance of molecular subtypes which were classified into EGFR exon 19 deletion on the first line afatinib monotherapy.BMC cancer · 2020Article
- Adaptive, Iterative, Long-Term Personalized Therapy Management in a Case of Stage IV Refractory NSCLC.Journal of personalized medicine · 2019Article
- Indel sensitive and comprehensive variant/mutation detection from RNA sequencing data for precision medicine.BMC medical genomics · 2018Article
- Altered conformational landscape and dimerization dependency underpins the activation of EGFR byProceedings of the National Academy of Sciences of the United States of America · 2018Article
- Uncommon frame-shift exon 19 EGFR mutations are sensitive to EGFR tyrosine kinase inhibitors in non-small cell lung carcinoma.Medical oncology (Northwood, London, England) · 2018Article
- Indel detection from RNA-seq data: tool evaluation and strategies for accurate detection of actionable mutations.Briefings in bioinformatics · 2017Article
- Identification of candidate genes for lung cancer somatic mutation test kits.Genetics and molecular biology · 2013Article
- Biomarker testing in non-small cell lung cancer: to move forward with quality.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2012Article
Corrections and comments
- Comment on
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Most lung adenocarcinoma-associated EGF receptor (EGFR) mutations confer sensitivity to specific EGFR tyrosine kinase inhibitors. The finding that exon 19 insertion mutations are also sensitive to this class of drugs suggests that testing for these mutations should be done and that these patients will benefit from treatment with tyrosine kinase inhibitors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.